Abstract
MPC-1304 ((±)-methyl 2-oxopropyl 1,4-dihydro 2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate, CAS 86780-90-7), a new calcium antagonist, was orally administered to 10 outpatients with mild essential hypertension. It was observed that MPC-1304 inhibited elevations of blood pressure both at rest and under exercise loading without any adverse hemodynamie effects. The findings obtained indicated that MPC-1304 would be clinically useful in the treatment of hypertensive patients undergoing therapy while continuing normal everyday activities including physical exertion.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1152-1156 |
| Number of pages | 5 |
| Journal | Arzneimittel-Forschung/Drug Research |
| Volume | 43 |
| Issue number | 11 |
| Publication status | Published - Jan 1 1993 |
Fingerprint
Keywords
- (±)-methyl 2-oxopropyl 1,4-dihydro 2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine dicarboxylate
- CAS 86780-90-7
- MPC-1304
- antihypertensives
- hypertension, essential
ASJC Scopus subject areas
- Drug Discovery
Cite this
Suzuki, S., Hashimoto, T., Kusano, S., Kapuku, K. G., Utsunomiya, T., & Yano, K. (1993). Effect of a new calcium antagonist on hemodynamics at rest and exercise loading in patients with essential hypertension. Arzneimittel-Forschung/Drug Research, 43(11), 1152-1156.